Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer - sprookjes - yvandenbroek - TriplyDB

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

http://www.wikidata.org/entity/Q26851421

about

Gene aberrations for precision medicine against lung adenocarcinoma Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis.Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report.A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.Tumor molecular profiling of NSCLC patients using next generation sequencing.5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction.Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients.A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Drug resistance profiles of mutations in the RET kinase domain TGF-β Signaling in Lung Health and Disease Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients Intestinal metastasis from primary ROS1 -positive lung adenocarcinoma cancer patients responding to crizotinib

P2860

Q26749348-BDC89729-5A84-4491-9394-80CEC9654A7D Q26781994-8DA35772-8620-48E5-B430-0C3DAACAD190 Q33876861-7A619C78-CFB5-4950-8136-E903267B3933 Q36945837-A1324124-5A8F-40ED-B121-DE08B4DA46F8 Q37162291-11167CEE-F90E-4D00-8E94-8166B6B12D3F Q37166233-DA4EF477-D4A9-4E1B-A272-8471CAFA198F Q37353957-BCC82E40-4D4D-4E32-BB25-A0BBE2842A99 Q37373037-CEB70413-F9B5-4143-A171-2EC5B0BF0CD0 Q37392650-5C79266B-0A9B-4EB9-A9B9-50325E94351B Q37688390-F177801F-2E15-4EBC-95B5-172580743175 Q37718370-A012CBF4-0238-47DB-ADA4-DC1237C087E0 Q38753582-D46F29D4-70F0-4C17-802D-105016477E9E Q39129178-59AB2B6E-6334-4FF2-9C99-B71217050D88 Q39641416-231E6198-5F42-410D-B7BE-35577A10D99E Q40070868-0F95634C-3C6E-4E5F-8D20-3324D8131902 Q41162171-B78FA60A-7650-42EF-BBA7-6A3004D3EB80 Q41492859-104B23E7-B2EA-41B2-A49C-AC7DF57F3951 Q42367902-B3450496-F580-4760-BA85-8656E2891AC5 Q45907759-F9B2EE3B-C03A-4D5E-8E07-F0DF480AA89F Q47139758-A0CDB151-2231-41A8-91A2-BFACB29143E1 Q47152298-9F737E1F-63BB-4977-A908-4DF540558772 Q47654457-DD7E535B-BD3F-44A4-8E9F-EAC396EF63C1 Q47710730-E06BFC68-0EF9-422A-A7EA-B5578BF85B41 Q52627231-D6DF2F92-10D2-42E1-BD86-14B51AE2A517 Q54091429-99FCB9E4-4978-468B-8342-CA539876FBAA Q55343122-6DDD73E8-145A-4542-B1C5-0575128AD5A7 Q55479808-06A4DE03-A211-4B7A-B250-3A65892ABFA0 Q55515297-7A24792F-5A00-4F9F-B4DD-81E3CEF4C8D3 Q58044610-B95E9EB5-034A-43D1-8D52-BA86F66461DA Q58734182-2EA02BB3-EA1F-4DE1-8298-F3F97472BE69 Q58787276-FB073B60-D9D4-4CED-8C88-BA8FE9A732B6 Q59135051-8980A01C-8599-4A57-B9E9-7C8E800E1F7A

P2860

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

http://www.wikidata.org/entity/Q26851421

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@ast

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@en

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@nl

type

label

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@ast

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@en

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@nl

prefLabel

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@ast

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@en

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@nl

P1433

Q26851421-EBB5E1E8-8C8D-467D-B5B0-A7CD78C47A67

P1476

Q26851421-CC14BDCB-0C50-476D-AB1B-94AA85C79F5D

P2093

Q26851421-3B550882-5D5E-4D3C-B820-D57AC77D5594

Q26851421-6A0F0EC2-5CBD-4F66-87A4-9737F5B661CD

Q26851421-90C96A18-D141-4C0F-9F32-96D5CB3406D2

Q26851421-A4E97B30-85A5-4ED0-A534-D5268C180EB4

Q26851421-BC8DA37A-B10F-4473-B2AB-20D1A34E1701

Q26851421-E2DFA76B-F1DA-40DA-8B9B-6D61A23EB061

Q26851421-EFE1042B-0FE0-4E55-995E-15D68DEC98E3

P2860

Q26851421-0B3AB7AA-AF52-4F88-B1D5-9835D23B425B

Q26851421-0E0884E0-ECCA-40BE-BFBF-A98D618D79BC

Q26851421-130085DC-C602-4731-BC2C-80C0D8F9C104

Q26851421-164C3EAB-7B69-4F7D-97D3-979E1870771C

Q26851421-185A09A8-FD90-4A5A-8F75-F5095569DF64

Q26851421-1C0A8D47-249A-4B9B-BD90-A2A1D8BECF15

Q26851421-2150C488-0FDC-4756-83F3-EFFBAD64C6AD

Q26851421-301F9365-B43C-4EF7-A9B3-F716594903A1

Q26851421-31F16144-D667-43E3-88C2-86B92C97F6F5

Q26851421-38F2DDB9-5D39-4241-9FCE-3E7D332C19D8

P304

Q26851421-32DFF671-F8E7-4A2E-8EED-E4E9E4A902E1

P31

Q26851421-C20809CA-E687-4459-9DC6-14CE6F9FDC41

P3181

Q26851421-90691890-431D-4D7D-BB8D-7A042724D0AA

P356

Q26851421-44CDF44B-D1BC-4683-9E9D-203B74104BF3

P407

Q26851421-6EA62146-2073-4E10-90DE-57ACC455C14D

P433

Q26851421-2DFBA0BA-9424-495D-AC07-A6A74EB45513

P478

Q26851421-703062E7-1743-4406-A440-1CAFD1F6D321

P577

Q26851421-1A0BAC61-CF91-4F0C-9766-8C9F7D1C3016

P5875

Q26851421-4F4BFA9E-FFED-4FF2-8BA8-2ECBCB8A13F4

P698

Q26851421-E8983D9A-CF57-4E4A-AA12-84B6327C53AE

P932

Q26851421-286C371C-8A29-419B-96E5-C9BE35A9E903

P3181

P356

J.ISSN.2218-6751.2014.11.11

P1433

Translational lung cancer research

P1476

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

@en

P2093

Goto K

http://www.w3.org/2001/XMLSchema#string

Kohno T

http://www.w3.org/2001/XMLSchema#string

Matsumoto S

http://www.w3.org/2001/XMLSchema#string

Nakaoku T

http://www.w3.org/2001/XMLSchema#string

Tsuchihara K

http://www.w3.org/2001/XMLSchema#string

Tsuta K

http://www.w3.org/2001/XMLSchema#string

Yoh K

http://www.w3.org/2001/XMLSchema#string

P2860

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Identification of targetable FGFR gene fusions in diverse cancers.

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Comprehensive molecular profiling of lung adenocarcinoma.

Transforming fusions of FGFR and TACC genes in human glioblastoma.

RET fusion gene: translation to personalized lung cancer therapy

P304

156-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1358196

http://www.w3.org/2001/XMLSchema#string

P356

10.3978/J.ISSN.2218-6751.2014.11.11

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274964956

http://www.w3.org/2001/XMLSchema#string

P698

25870798

http://www.w3.org/2001/XMLSchema#string

P932

4384213

http://www.w3.org/2001/XMLSchema#string